Sort
10,766 grants matching “checkpoint inhibitor”
Reorienting the Glioblastoma Microenvironment to Respond to Immunotherapy
$575,374Mary Helen Barcellos-Hoff · University Of California, San Francisco · R01 · FY2022 · NS
Molecular and immunological heterogeneity of Small Cell Lung Cancer (SCLC) and its impact on relapse and therapeutic response
$575,245Lauren Averett Byers · University Of Tx Md Anderson Can Ctr · U01 · FY2024 · CA
Translating Autoantibodies Into Chimeric Antigen Receptor-T cell Therapy for Small Cell Lung Cancer
$575,240Kristin J Lastwika · Fred Hutchinson Cancer Center · U01 · FY2022 · CA
Project 1: Targeting Metabolic Dependencies in PDAC
$575,225Ronald Anthony Depinho · University Of Tx Md Anderson Can Ctr · P01 · FY2016 · CA
Reorienting the Glioblastoma Microenvironment to Respond to Immunotherapy
$575,119Mary Helen Barcellos-Hoff · University Of California, San Francisco · R01 · FY2023 · NS
Targeting adrenergic stress pathways to Increase tumor sensitivity to radiation and promote development of an anti-tumor immune response
$574,981Elizabeth Repasky · Roswell Park Cancer Institute Corp · R01 · FY2019 · CA
Homologous recombination deficiency and beyond in pancreatic cancer: evaluating the regulators of response to pembrolizumab and olaparib (POLAR) from the immune and genomic perspectives
$574,981Eileen Mary O'Reilly · Sloan-Kettering Inst Can Research · P50 · FY2023 · CA
The role of Galectin-1 in shaping the immune suppressive landscape in head and neck cancer
$574,961Quynh-Thu X Le · Stanford University · R01 · FY2021 · DE
Radiogenomic Credentialing of Head and Neck Cancer Models
$574,775Mukund Seshadri · Roswell Park Cancer Institute Corp · R01 · FY2025 · CA
Finding the optimal balance of immunotherapy efficacy and toxicity.
$574,731David Eric Gerber · Ut Southwestern Medical Center · U01 · FY2022 · AI
G alpha-q/11 Signaling and Inhibition in Ocular Melanoma
$574,451Kendall Jay Blumer · Washington University · R01 · FY2019 · CA
Targeting Amino Acid Metabolism in Glioblastoma
$574,427Jeremy N Rich · University Of Pittsburgh At Pittsburgh · R01 · FY2024 · NS
Development of Physiologic Tissue Models to Assess Tumor Explant Response to Immune Checkpoint Blockade
$574,170Roger D. Kamm · Massachusetts Institute Of Technology · U01 · FY2017 · CA
Ascorbic acid as a pharmacologic agent in disease treatment
$574,156Mark A Levine · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2025 · DK
Regulation and Function of Stromal Macropinocytosis in Pancreatic Ductal Adenocarcinoma
$574,084Cosimo Commisso · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2022 · CA
Regulation and Function of Stromal Macropinocytosis in Pancreatic Ductal Adenocarcinoma
$574,084Cosimo Commisso · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2023 · CA
The Role of the Tumor Suppressor ARID1A in R loop Homeostasis and Tumor Immunity
$573,836Diana Clare Hargreaves · Salk Institute For Biological Studies · R01 · FY2025 · CA
Control of cell cycle commitment by APC-C-Cdh1
$573,763Steven Cappell · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
Novel therapeutic approaches for enhancing anti-tumor immunity in SCLC
$573,659John V. Heymach · University Of Tx Md Anderson Can Ctr · U01 · FY2019 · CA
Elucidating genetics of response to immune checkpoint blockade in lung cancer
$573,644Naiyer A Rizvi · Columbia University Health Sciences · R01 · FY2017 · CA
TARGETING A STRESS-DERIVED IMMUNOSUPPRESSIVE ADENOSINE PATHWAY IN TUMORS RESISTANT TO CHECKPOINT INHIBITORS
$573,618The University Of Texas At El Paso · · FY2019 · Defense Health Agency
Neutrophil derived proteinases abolish the IFNG signature in NSCLC
$573,105A. McGarry Houghton · Fred Hutchinson Cancer Center · R01 · FY2023 · CA
Credentialing Models of Invasive Lobular Breast Cancer for Translational Research
$573,041Steffi Oesterreich · University Of Pittsburgh At Pittsburgh · R01 · FY2021 · CA
Development of selective HDAC6 inhibitors to improve cancer immunotherapy
$573,024Alejandro V Villagra · Georgetown University · R01 · FY2025 · CA
A Prospective Cohort Study of Patients with Non-Small Cell Lung Cancer and Multiple Myeloma to Assess the Benefits and Harms Related to Cannabis Use During Treatment
$572,907Richard T Lee · Beckman Research Institute/City Of Hope · U01 · FY2024 · CA